Trends in hypertension care in eastern and south-western Finland during 1982-2002

Journal of Hypertension

Volumn 24, Issue 5, 2006, Pages 829-836

  Kastarinen, Mika J ^a,b   Antikainen, Riitta L ^b,c   Laatikainen, Tuna K ^d   Salomaa, Veikko V ^d   Tuomilehto, Jaakko O ^d,e,f   Nissinen, Aulikki M ^d,g   Vartiainen, Erkki A ^d  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF OULU   (Finland)

^c Oulu City Hospital   (Finland)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^e UNIVERSITY OF HELSINKI   (Finland)

^f SOUTH OSTROBOTHNIA CENTRAL HOSPITAL   (Finland)

^g UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Awareness; Control of hypertension; Cross sectional population survey; Finland; Hypertension; Hypertension guidelines; Prevalence

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; DIASTOLIC BLOOD PRESSURE; FEMALE; FINLAND; HEALTH SURVEY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MEDICAL SOCIETY; PATIENT CARE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REGISTER; RISK FACTOR; SYSTOLIC BLOOD PRESSURE;

EID: 33646384162     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000222751.90443.0a     Document Type: Article

References (45)

1. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med 1993; 153:598-615.
2. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996; 275:1571-1576.
3. Staessen JA, Wang J, Thijs L. Cardiovascular prevention and blood pressure reduction: a qualitative overview updated until 1 March 2003. J Hypertens 2003; 21:1055-1076.
4. Bulpitt CJ, Beevers DG, Butler A, Coles EC, Hunt D, Munro-Faure AD, et al. The survival of treated hypertensive patients and their causes of death: a report from the DHSS hypertensive care computing project (DHCCP). J Hypertens 1986; 4:93-99.
5. Stamler J, Wentworth D, Neaton JD. Prevalence and prognostic significance of hypercholesterolemia in men with hypertension. Prospective data on the primary screenees of the Multiple Risk Factor Intervention Trial. Am J Med 1986; 80:33-39.
6. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053.
7. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al. British Hypertension Society Guidelines for hypertension management 2004 (BHS-IV). BMJ 2004; 328:634-640.
8. Primatesta P, Brookes M, Poulter NR. Improved hypertension management and control: results from the health survey for England 1998. Hypertension 2001; 38:827-832.
9. Marques-Vidal P, Ruidavets JB, Cambou JB, Ferrieres J. Trends in hypertension prevalence and management in Southwestern France, 1985-1996. J Clin Epidemiol 2000; 53:1230-1235.
10. Gasse C, Hense HW, Stieber J, Doring A, Liese AD, Keil U. Assessing hypertension management in the community: trends of prevalence, detection, treatment and control of hypertension in the MONICA Project, Augsburg 1984-1995. J Hum Hypertens 2001; 15:27-36.
11. Cifkova R, Skodova Z, Lanska V, Adamkova V, Novozamska E, Petrzilkova Z, et al. Trends in blood pressure levels, prevalence, awareness, treatment, and control of hypertension in Czech population from 1985 to 2000/2001. J Hypertens 2004; 22:1479-1485.
12. Psaltopoulou T, Orfanos P, Naska A, Lenas D, Trichopoulos D, Trichopoulou A. Prevalence, awareness, treatment and control of hypertension in a general population sample of 26,913 adults in the Greek EPIC study. Int J Epidemiol 2004; 6:1345-1352.
13. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003; 290:199-206.
14. Joffres MR, Hamet P, Maclean DR, L'Italien GJ, Fodor G. Distribution of blood pressure and hypertension in Canada and the United States. Am J Hypertens 2001; 14:1099-1105.
15. Gu D, Reynolds K, Wu X, Chen J, Duan X, Muntner P, et al., for the InterASIA Collaborative Group. Prevalence, awareness, treatment, and control of hypertension in China. Hypertension 2002; 40:920-927.
16. Jo I, Ahn Y, Lee J, Shin KR, Lee HK, Shin C. Prevalence, awareness, treatment, control and risk factors of hypertension in Korea: the Ansan study. J Hypertens 2001; 19:1523-1532.
17. Kastarinen MJ, Salomaa VV, Vartiainen EA, Jousilahti PJ, Tuomilehto JO, Puska PM, Nissinen AM. Trends in blood pressure levels and control of hypertension in Finland from 1982 to 1997. J Hypertens 1998; 16:1379-1387.
18. WHO MONICA Project Principal Investigators. The World Health Organization MONICA Project (Monitoring trends and determinants in cardiovascular disease): a major international collaboration. J Clin Epidemiol 1988; 41:105-114.
19. WHO Monica Project. MONICA manual, part III: population survey. Available at: http://ww.ktl.fi/publications/monica/manual/part3/iii-1.htm. Accessed: 2 February 2006.
20. Tolonen H, Kuulasmaa K, Laatikainen T, Wolf H. European Health Risk Monitoring Project. Recommendation for indicators, international collaboration, protocol and manual operations of chronic disease risk factor surveys; 2002. Available at: http://ww.ktl.fi/ehrm. Accessed: 2 February 2006.
21. Kostner GM. Enzymatic determination of cholesterol in high density lipoprotein fraction prepared by polyanion precipitation. Clin Chem 1976; 22:695-701.
22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499-502.
23. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24:987-1003.
24. Nissinen A, Tuomilehto J, Salomaa V, Puska P. Hypertension control. In: Puska, P, Tuomilehto, J, Nissinen, A, Vartiainen, E, editors. The North Karelia Project. 20 Year results and experiences. Helsinki: National Public Health Institute; 1995. pp. 95-105.
25. Pietinen P, Lahti-Koski M, Vartiainen E, Puska P. Nutrition and cardiovascular disease in Finland since the early 70s: a success story. J Nutr Health Aging 2001; 5:150-154.
26. Barengo NC, Nissinen A, Tuomilehto J, Pekkarinen H. Twenty-five-year trends in physical activity of 20- to 59-year old populations in eastern Finland. Med Sci Sports Exerc 2001; 34:1302-1307.
27. Kastarinen MJ, Nissinen AM, Vartiainen EA, Jousilahti PJ, Korhonen HJ, Puska PM, Tuomilehto JO. Blood pressure levels and obesity trends in hypertensive and normotensive Finns during 1982-1997. J Hypertens 2000; 18:255-262.
28. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada and United States. JAMA 2003; 289:2363-2369.
29. National High Blood Pressure Education Program. Working group report on primary prevention of hypertension. Arch Intern Med 1993; 153:186-208.
30. Steckelings UM, Stoppelhaar M, Sharma AM, Wittchen HU, Krause P, Kupper P, et al., for the HYDRA Study Group. HYDRA: possible determinants of unsatisfactory hypertension control in German primary care patients. Blood Press 2004; 13:80-88.
31. Cuspidi C, Michev I, Meani S, Severgnini B, Sala C, Salerno M, et al., for the Lombardy Regional Section of the Italian Society of Hypertension. Awareness of hypertension guidelines in primary care: results of a regionwide surveys in Italy. J Hum Hypertens 2003; 17:541-547.
32. Persson M, Carlberg B, Tavelin B, Lindholm LH. Doctor's estimation of cardiovascular risk and willingness to give drug treatment in hypertension: fair risk assessment but defensive treatment policy. J Hypertens 2004; 22:65-71.
33. Ch Yiannakopoulou E, Papadupulos JS, Cokkinos DV, Mountokalakis TD. Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil 2005; 12: 243-249.
34. Bramlage P, Pittrow D, Wittchen HU, Kirsch W, Boehler S, Lehnert H, et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens 2004; 17:904-910.
35. Degli Esposti E, Di Martino M, Sturani A, Russo P, Dradi C, Falcinell S, Buda S. Risk factors for uncontrolled hypertension in Italy. J Hum Hypertens 2004; 18:207-213.
36. Petrella RJ, Campbell NR. Awareness and misconception of hypertension in Canada: results of a national survey. Can J Cardiol 2005; 21:589-593.
37. Lloyd-Jones DM, Evans JC, Larson MG, O'Donnell CJ, Roccella EJ, Levy D. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension 2000; 36:594-599.
38. Fahey TP, Peters TJ. What constitutes controlled hypertension? Patient based comparison of hypertension guidelines. BMJ 1996; 313:93-96.
39. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al., and the National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252.
40. Yikona JI, Wallis EJ, Ramsay LE, Jackson PR. Coronary and cardiovascular risk estimation in uncomplicated mild hypertension. A comparison of risk assessment methods. J Hypertens 2002; 20:2173-2182.
41. Persson M, Carlberg B, Weinehall L, Nilsson L, Stegmayr B, Lindholm LH. Risk stratification by guidelines compared with risk assessment by risk equations applied to a MONICA sample. J Hypertens 2003; 21:1089-1095.
42. Montgomery AA, Fahey T, Peters TJ, MacIntosh C, Sharp DJ. Evaluation of computer based clinical decision support system and risk chart for management of hypertension in primary care: randomised controlled trial. BMJ 2000; 320:686-690.
43. PROGRESS Collaborative Study Group. Randomised trial of perindropril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358:1033-1041.
44. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-153.
45. Cuspidi C, Meani S, Salerno M, Severgnini B, Fusi V, Valerio C, et al. Cardiovascular risk stratification according to the 2003 ESH-ESC guidelines in uncomplicated patients with essential hypertension: comparison with the 1999 WHO/ISH guidelines criteria. Blood Press 2004; 13:144-151.